亚叶酸钙联合氟尿嘧啶加或不加奥沙利铂作为晚期结直肠癌一线治疗
这项III期研究将420例既往未治疗的晚期结直肠癌患者随机分配至LV5FU2方案或LV5FU2联合奥沙利铂方案,主要终点为无进展生存期。联合奥沙利铂组无进展生存期显著延长(中位9.0个月 vs 6.2个月,P=.0003),缓解率更高(50.7% vs 22.3%,P=.0001),总生存改善未达显著(中位16.2个月 vs 14.7个月,P=.12)。
要点
- 奥沙利铂联合LV5FU2较LV5FU2单用显著延长无进展生存期(中位9.0个月 vs 6.2个月,P=.0003)。
- 联合组缓解率显著更高(50.7% vs 22.3%,P=.0001),总生存改善未达显著(中位16.2个月 vs 14.7个月,P=.12)。
- 联合组3/4级中性粒细胞减少、腹泻和3级神经感觉毒性发生率更高,但生活质量未受损。
核心结论
- LV5FU2联合奥沙利铂作为晚期结直肠癌一线治疗似乎有益,表现为无进展生存期延长、耐受性可接受且生活质量得以维持。
研究设计与样本
- III期随机对照研究,纳入420例既往未治疗、有可测量病灶的晚期结直肠癌患者。
主要发现
- 奥沙利铂联合LV5FU2组较对照组无进展生存期显著延长(中位9.0个月 vs 6.2个月,P=.0003)。
- 联合组缓解率显著更高(50.7% vs 22.3%,P=.0001)。
- 总生存改善未达显著(中位16.2个月 vs 14.7个月,P=.12)。
- 联合组3/4级中性粒细胞减少发生率41.7% vs 5.3%,3/4级腹泻11.9% vs 5.3%,3级神经感觉毒性18.2% vs 0%。
- 联合组无疾病进展或总体健康状况恶化的生存期更长(P=.004)。
关键数值与推荐
- LV5FU2方案:亚叶酸钙200 mg/m2/d静脉输注2小时,随后氟尿嘧啶400 mg/m2/d静脉推注及600 mg/m2/d持续22小时输注,连续2天,每2周重复。
- 奥沙利铂85 mg/m2第1天静脉输注2小时。
临床怎么用
- 作者认为LV5FU2联合奥沙利铂作为晚期结直肠癌一线治疗似乎有益,可延长无进展生存期且耐受性可接受并维持生活质量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen. This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point. PATIENTS AND METHODS: Four hundred twenty previously untreated patients with measurable disease were randomized to receive a 2-hour infusion of LV (200 mg/m2/d) followed by a 5FU bolus (400 mg/m2/d) and 22-hour infusion (600 mg/m2/d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1. RESULTS: Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P = .0003) and better response rate (50.7% v 22.3%; P = .0001) when compared with the control arm. The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P = .12). LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41.7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL). Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P = .004). CONCLUSION: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
引用
- de Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol. 2023. PMID: 37967516. doi:10.1200/JCO.22.02773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。